BILLERICA, Mass.--(BUSINESS WIRE)--
Bruker Corporation (NASDAQ: BRKR) today reported financial results for
its fourth quarter and full year ended December 31, 2013.
Bruker’s revenues for the fourth quarter of 2013 grew by 6.7 percent to
$552.1 million, compared to $517.3 million in the fourth quarter of
2012. Excluding a 0.4 percent positive effect from changes in foreign
exchange rates and a 0.1 percent net positive effect from acquisitions
and divestitures, Bruker reported organic revenue growth of 6.2 percent
year-over-year in the fourth quarter of 2013.
Bruker reported fourth quarter 2013 GAAP operating income of $61.0
million, or 11.0% of revenues, compared to $39.2 million, or 7.6% of
revenues, in the fourth quarter of 2012. Fourth quarter 2013 GAAP
earnings per diluted share (EPS) was $0.21, compared to EPS of $0.08 in
the fourth quarter of 2012.
On a non-GAAP basis, Bruker reported fourth quarter 2013 operating
income of $81.3 million, or 14.7% of revenues, compared to $73.0
million, or 14.1% of revenues, in the fourth quarter of 2012. Fourth
quarter 2013 non-GAAP EPS was $0.31, compared to $0.28 in the fourth
quarter of 2012. A reconciliation of GAAP to non-GAAP financial measures
is provided in the Company’s financial tables accompanying this press
release.
For the full year 2013, Bruker’s revenues grew 2.7 percent to $1.84
billion, compared to $1.79 billion for the full year 2012. Excluding a
0.3 percent unfavorable impact from changes in foreign exchange rates
and a 0.2 percent net negative effect from acquisitions and
divestitures, the Company generated 3.2 percent organic revenue growth
for the full year 2013.
Bruker reported GAAP operating income of $148.2 million, or 8.1% of
revenues, for the full year 2013, compared to $156.0 million, or 8.7% of
revenues, for the full year 2012. The Company’s GAAP EPS for the full
year 2013 was $0.48, compared to $0.46 for the full year 2012.
On a non-GAAP basis, Bruker reported operating income of $205.5 million,
or 11.2% of revenues, for the full year 2013, compared to $219.0
million, or 12.2% of revenues, for the full year 2012. Non-GAAP EPS for
the full year 2013 was $0.77, compared to $0.83 for the full year 2012.
Free cash flow for the full year 2013 was $94.7 million, compared to
$60.3 million for the full year 2012.
“We ended 2013 on a stronger note, with healthy revenue growth and
improving free cash flow,” said Frank Laukien, President and CEO of
Bruker. “Over the past eighteen months, we have taken steps to transform
Bruker into a stronger company, while continuing to emphasize product
innovations. These steps have included: expanding our leadership team;
adopting our new Group structure; improving our operational processes
and infrastructure; and implementing cost savings initiatives that are
expected to generate $15 to $20 million of annual savings. While our
full year 2013 financial performance does not yet fully reflect our
underlying progress, we are confident that our multi-year innovation and
transformation efforts are proceeding well, and we expect to deliver
attractive growth and operating leverage in 2014 and beyond.”
Laukien continued: “Looking ahead to 2014, we feel better about the
health of our core academic and government customers and about our
prospects in the clinical research and diagnostics markets, but we
remain cautious about demand from the industrial markets. Overall, we
expect to generate year-over-year revenue growth of approximately 3 to 4
percent, and non-GAAP EPS growth of 10 to 14 percent, for the full year
2014.”
“Our higher full year 2013 free cash flow performance is a reflection of
the gradual progress we are making in improving our working capital
efficiency and lowering our capital expenditures,” said Charles Wagner,
Chief Financial Officer of Bruker. “While we did an effective job of
lowering our operating expenses and launching new restructuring
initiatives during the year 2013, these actions were not enough to
compensate for losing more than 100 basis points of operating margin due
to changes in foreign exchange rates during 2013. Moving forward, we are
well-positioned to drive margin expansion and further cash flow
improvements in 2014 and subsequent years.”
Quarterly Earnings Call
Bruker will host a conference call and webcast to discuss its financial
results, business outlook, and related corporate and financial matters
at 4:45 p.m. Eastern Time today. To listen to the webcast, investors can
go to http://ir.bruker.com
and click on the live webcast hyperlink. A slide presentation that will
be referenced during the webcast will be posted to the Company’s website
shortly before the webcast begins. Investors can also listen to the
earnings webcast via telephone by dialing 1-877-270-2148 or
+1-412-902-6510, and referencing “Bruker’s Fourth Quarter 2013 Earnings
Conference Call”. A telephone replay of the conference call will be
available by dialing 1-877-344-7529 or +1-412-317-0088 and entering
conference number: 10039920. The replay will be available beginning one
hour after the end of the conference through February 24, 2014 at 9:00
a.m. ET.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used by Bruker Corporation in this press
release are non-GAAP gross profit; non-GAAP gross profit margin;
non-GAAP operating income; non-GAAP operating margin; non-GAAP interest
and other income (expense) net; non-GAAP profit before tax; non-GAAP tax
rate; non-GAAP net income; non-GAAP earnings per share; and free cash
flow. These non-GAAP measures exclude costs related to restructuring
costs, acquisition and related integration expenses, amortization of
acquired intangible assets and other costs that are non-recurring in
nature. There are limitations in using non-GAAP financial measures as
they are not prepared in accordance with U.S. generally accepted
accounting principles and may be different from non-GAAP financial
measures used by other companies.
We believe that the non-GAAP financial measures provide useful and
supplementary information to investors regarding our quarterly and
annual performance. It is our belief that these non-GAAP financial
measures are particularly important as Bruker implements restructuring
initiatives to expand operating margins. The financial impact of these
activities, particularly restructuring activities, can be large and may
adversely affect the comparability of our results from period-to-period.
We define free cash flow as net cash provided by operating activities
less additions to property, plant, and equipment. We believe free cash
flow is a useful measure to evaluate our business as it indicates the
amount of cash generated after additions to property, plant, and
equipment that is available for, among other things, strategic
acquisitions, investments in our business, and repayment of debt.
We regularly use non-GAAP financial measures internally to understand,
manage, and evaluate our business results and make operating decisions.
We also measure our employees and compensate them, in part, based on
such non-GAAP measures. For the same reasons, we also use this
information for our forecasting activities.
Non-GAAP financial measures should not be considered as a substitute
for, or superior to, measures of financial performance prepared in
accordance with GAAP. The non-GAAP financial measures are meant to
supplement, and to be viewed in conjunction with, GAAP financial
measures. They are limited in value because they exclude charges that
have a material effect on our reported results and, therefore, should
not be relied upon as the sole financial measures to evaluate our
financial results. Investors are encouraged to review the reconciliation
of the financial measures to their most directly comparable GAAP
financial measures as provided in the tables accompanying this press
release.
Forward Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties that could
cause actual results to differ materially from those projected,
including, but not limited to, risks and uncertainties relating to
adverse changes in conditions in the global economy and volatility in
the capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product development
and market acceptance of our products, the cost and pricing of our
products, manufacturing, competition, dependence on collaborative
partners and key suppliers, capital spending and government funding
policies, the outcome of any actions that may be taken by government
agencies in connection with FCPA compliance matters we have disclosed to
them, changes in governmental regulations, realization of anticipated
benefits from economic stimulus programs, intellectual property rights,
litigation, exposure to foreign currency fluctuations and other risk
factors discussed from time to time in our filings with the Securities
and Exchange Commission. These and other factors are identified and
described in more detail in our filings with the SEC, including, without
limitation, our annual report on Form 10-K for the year ended December
31, 2012, our most recent quarterly report on Form 10-Q and our current
reports on Form 8-K. We expressly disclaim any intent or obligation to
update these forward-looking statements other than as required by law.
-tables follow-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker Corporation
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions)
|
|
December 31,
|
|
|
|
|
|
December 31,
|
|
|
|
|
|
2013
|
|
|
|
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
438.7
|
|
|
|
|
|
$
|
310.6
|
|
Accounts receivable, net
|
|
307.6
|
|
|
|
|
|
|
289.3
|
|
Inventories
|
|
|
589.8
|
|
|
|
|
|
|
611.5
|
|
Other current assets
|
|
95.8
|
|
|
|
|
|
|
98.3
|
|
|
Total current assets
|
|
1,431.9
|
|
|
|
|
|
|
1,309.7
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
299.5
|
|
|
|
|
|
|
283.6
|
Intangible and other long-term assets
|
|
256.9
|
|
|
|
|
|
|
263.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
1,988.3
|
|
|
|
|
|
$
|
1,856.4
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
Current portion of long-term debt
|
$
|
0.7
|
|
|
|
|
|
$
|
1.3
|
|
Accounts payable
|
|
74.8
|
|
|
|
|
|
|
69.6
|
|
Customer advances
|
|
258.6
|
|
|
|
|
|
|
267.3
|
|
Other current liabilities
|
|
314.5
|
|
|
|
|
|
|
343.6
|
|
|
Total current liabilities
|
|
648.6
|
|
|
|
|
|
|
681.8
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
354.3
|
|
|
|
|
|
|
335.9
|
Other long-term liabilities
|
|
135.2
|
|
|
|
|
|
|
129.0
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders' equity
|
|
850.2
|
|
|
|
|
|
|
709.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders' equity
|
$
|
1,988.3
|
|
|
|
|
|
$
|
1,856.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker Corporation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
Twelve Months Ended
|
(in millions, except per share amounts)
|
|
|
December 31,
|
|
|
|
|
December 31,
|
|
|
|
|
|
2013
|
|
|
|
2012
|
|
|
|
|
2013
|
|
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
$
|
552.1
|
|
|
|
|
$
|
517.3
|
|
|
|
|
|
$
|
1,839.4
|
|
|
|
|
$
|
1,791.4
|
|
Cost of revenues
|
|
|
|
316.2
|
|
|
|
|
|
275.6
|
|
|
|
|
|
|
1,034.2
|
|
|
|
|
|
962.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
235.9
|
|
|
|
|
|
241.7
|
|
|
|
|
|
|
805.2
|
|
|
|
|
|
829.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
|
118.3
|
|
|
|
|
|
124.0
|
|
|
|
|
|
|
437.9
|
|
|
|
|
|
440.4
|
|
Research and development
|
|
|
|
49.1
|
|
|
|
|
|
50.3
|
|
|
|
|
|
|
190.5
|
|
|
|
|
|
195.3
|
|
Impairment of assets
|
|
|
|
-
|
|
|
|
|
|
23.8
|
|
|
|
|
|
|
-
|
|
|
|
|
|
23.8
|
|
Other charges, net
|
|
|
|
7.5
|
|
|
|
|
|
4.4
|
|
|
|
|
|
|
28.6
|
|
|
|
|
|
13.9
|
|
Total operating expenses
|
|
|
|
174.9
|
|
|
|
|
|
202.5
|
|
|
|
|
|
|
657.0
|
|
|
|
|
|
673.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
61.0
|
|
|
|
|
|
39.2
|
|
|
|
|
|
|
148.2
|
|
|
|
|
|
156.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and other income (expense), net
|
|
|
|
(7.2
|
)
|
|
|
|
|
(4.7
|
)
|
|
|
|
|
|
(23.6
|
)
|
|
|
|
|
(17.7
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes and noncontrolling
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
interest in consolidated subsidiaries
|
|
|
|
53.8
|
|
|
|
|
|
34.5
|
|
|
|
|
|
|
124.6
|
|
|
|
|
|
138.3
|
|
Income tax provision
|
|
|
|
17.9
|
|
|
|
|
|
21.2
|
|
|
|
|
|
|
42.8
|
|
|
|
|
|
60.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net income
|
|
|
|
35.9
|
|
|
|
|
|
13.3
|
|
|
|
|
|
|
81.8
|
|
|
|
|
|
78.2
|
|
Net income attributable to noncontrolling
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
interests in consolidated subsidiaries
|
|
|
|
0.7
|
|
|
|
|
|
0.5
|
|
|
|
|
|
|
1.7
|
|
|
|
|
|
0.7
|
|
Net income attributable to Bruker Corporation
|
|
|
$
|
35.2
|
|
|
|
|
$
|
12.8
|
|
|
|
|
|
$
|
80.1
|
|
|
|
|
$
|
77.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share attributable to
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker Corporation shareholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
$
|
0.21
|
|
|
|
|
$
|
0.08
|
|
|
|
|
|
$
|
0.48
|
|
|
|
|
$
|
0.47
|
|
|
Diluted
|
|
|
$
|
0.21
|
|
|
|
|
$
|
0.08
|
|
|
|
|
|
$
|
0.48
|
|
|
|
|
$
|
0.46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
167.2
|
|
|
|
|
|
166.2
|
|
|
|
|
|
|
166.5
|
|
|
|
|
|
166.0
|
|
|
Diluted
|
|
|
|
169.0
|
|
|
|
|
|
167.7
|
|
|
|
|
|
|
168.5
|
|
|
|
|
|
167.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker Corporation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions)
|
|
|
|
|
Three Months Ended December 31,
|
|
|
|
Twelve Months Ended December 31,
|
|
|
|
|
|
|
|
|
|
|
2013
|
|
|
|
|
|
2012
|
|
|
|
|
|
2013
|
|
|
|
|
|
2012
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net income
|
|
|
|
$
|
35.9
|
|
|
|
|
$
|
13.3
|
|
|
|
|
$
|
81.8
|
|
|
|
|
$
|
78.2
|
|
Adjustments to reconcile consolidated net income to cash flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
15.9
|
|
|
|
|
|
16.6
|
|
|
|
|
|
61.3
|
|
|
|
|
|
59.1
|
|
|
|
|
|
Write-down of demonstration inventories to net realizable value
|
|
|
|
8.7
|
|
|
|
|
|
8.9
|
|
|
|
|
|
32.7
|
|
|
|
|
|
31.5
|
|
|
|
|
|
Impairment of assets
|
|
|
|
|
-
|
|
|
|
|
|
23.8
|
|
|
|
|
|
-
|
|
|
|
|
|
23.8
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
|
1.8
|
|
|
|
|
|
1.9
|
|
|
|
|
|
6.6
|
|
|
|
|
|
7.8
|
|
|
|
|
|
Deferred income taxes
|
|
|
|
|
22.1
|
|
|
|
|
|
(11.4
|
)
|
|
|
|
|
14.0
|
|
|
|
|
|
(11.7
|
)
|
|
|
|
|
Gain on disposal of product line
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
(0.9
|
)
|
|
|
|
|
(2.2
|
)
|
|
|
|
|
Other non-cash expenses, net
|
|
|
|
0.9
|
|
|
|
|
|
2.8
|
|
|
|
|
|
2.1
|
|
|
|
|
|
4.9
|
|
Changes in operating assets and liabilities, net of acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
|
|
(9.6
|
)
|
|
|
|
|
(23.6
|
)
|
|
|
|
|
(19.3
|
)
|
|
|
|
|
1.6
|
|
|
|
|
|
Inventories
|
|
|
|
|
|
40.6
|
|
|
|
|
|
23.4
|
|
|
|
|
|
5.7
|
|
|
|
|
|
(49.5
|
)
|
|
|
|
|
Accounts payable and accrued expenses
|
|
|
|
1.3
|
|
|
|
|
|
15.6
|
|
|
|
|
|
7.0
|
|
|
|
|
|
4.6
|
|
|
|
|
|
Income taxes payable
|
|
|
|
|
(32.6
|
)
|
|
|
|
|
8.2
|
|
|
|
|
|
(40.3
|
)
|
|
|
|
|
(2.4
|
)
|
|
|
|
|
Deferred revenue
|
|
|
|
|
3.3
|
|
|
|
|
|
3.2
|
|
|
|
|
|
4.6
|
|
|
|
|
|
(4.4
|
)
|
|
|
|
|
Customer advances
|
|
|
|
|
6.8
|
|
|
|
|
|
(1.8
|
)
|
|
|
|
|
(12.1
|
)
|
|
|
|
|
(4.6
|
)
|
|
|
|
|
Other changes in operating assets and liabilities, net
|
|
|
|
36.3
|
|
|
|
|
|
10.0
|
|
|
|
|
|
1.8
|
|
|
|
|
|
(3.6
|
)
|
Net cash provided by operating activities
|
|
|
|
131.4
|
|
|
|
|
|
90.9
|
|
|
|
|
|
145.0
|
|
|
|
|
|
133.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for acquisitions, net of cash acquired
|
|
|
|
-
|
|
|
|
|
|
(5.3
|
)
|
|
|
|
|
(11.6
|
)
|
|
|
|
|
(27.0
|
)
|
|
|
|
|
Disposal of product line
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
0.5
|
|
|
|
|
|
3.3
|
|
|
|
|
|
Purchases of property, plant and equipment
|
|
|
|
(9.0
|
)
|
|
|
|
|
(23.0
|
)
|
|
|
|
|
(50.3
|
)
|
|
|
|
|
(72.8
|
)
|
|
|
|
|
Sales of property, plant and equipment
|
|
|
|
0.6
|
|
|
|
|
|
0.8
|
|
|
|
|
|
1.4
|
|
|
|
|
|
3.3
|
|
Net cash used in investing activities
|
|
|
|
|
(8.4
|
)
|
|
|
|
|
(27.5
|
)
|
|
|
|
|
(60.0
|
)
|
|
|
|
|
(93.2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayments of revolving lines of credit
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
(216.5
|
)
|
|
|
|
|
Proceeds from revolving lines of credit
|
|
|
|
-
|
|
|
|
|
|
38.0
|
|
|
|
|
|
19.5
|
|
|
|
|
|
93.0
|
|
|
|
|
|
Proceeds from Note Purchase Agreement
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
240.0
|
|
|
|
|
|
Repayment of other debt, net
|
|
|
|
|
(0.8
|
)
|
|
|
|
|
(37.8
|
)
|
|
|
|
|
(1.6
|
)
|
|
|
|
|
(83.2
|
)
|
|
|
|
|
Payment of deferred financing costs
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
(1.4
|
)
|
|
|
|
|
Proceeds from issuance of common stock, net
|
|
|
|
0.3
|
|
|
|
|
|
0.9
|
|
|
|
|
|
8.3
|
|
|
|
|
|
4.5
|
|
|
|
|
|
Changes in restricted cash
|
|
|
|
|
2.2
|
|
|
|
|
|
0.1
|
|
|
|
|
|
0.9
|
|
|
|
|
|
(1.4
|
)
|
|
|
|
|
Cash payments to noncontrolling interest
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
(0.6
|
)
|
|
|
|
|
(0.6
|
)
|
Net cash provided by financing activities
|
|
|
|
1.7
|
|
|
|
|
|
1.2
|
|
|
|
|
|
26.5
|
|
|
|
|
|
34.4
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
|
7.2
|
|
|
|
|
|
3.9
|
|
|
|
|
|
16.6
|
|
|
|
|
|
(9.7
|
)
|
Net change in cash and cash equivalents
|
|
|
|
131.9
|
|
|
|
|
|
68.5
|
|
|
|
|
|
128.1
|
|
|
|
|
|
64.6
|
|
Cash and cash equivalents at beginning of period
|
|
|
|
306.8
|
|
|
|
|
|
242.1
|
|
|
|
|
|
310.6
|
|
|
|
|
|
246.0
|
|
Cash and cash equivalents at end of period
|
|
|
$
|
438.7
|
|
|
|
|
$
|
310.6
|
|
|
|
|
$
|
438.7
|
|
|
|
|
$
|
310.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruker Corporation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES* (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions, except per share amounts)
|
|
|
Three Months Ended December 31,
|
Twelve Months Ended December 31,
|
|
|
|
|
2013
|
|
|
|
|
|
2012
|
|
|
|
|
|
2013
|
|
|
|
|
|
2012
|
|
Reconciliation to Non-GAAP Operating Income, Non-GAAP Profit
Before Tax, Non-GAAP Net Income, and Non-GAAP EPS
|
|
|
|
GAAP Operating Income
|
|
|
$
|
61.0
|
|
|
|
|
$
|
39.2
|
|
|
|
|
$
|
148.2
|
|
|
|
|
$
|
156.0
|
|
Non-GAAP Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring Costs
|
|
|
|
11.7
|
|
|
|
|
|
0.5
|
|
|
|
|
|
25.3
|
|
|
|
|
|
0.9
|
|
Acquisition-Related Costs
|
|
|
|
2.3
|
|
|
|
|
|
0.2
|
|
|
|
|
|
4.5
|
|
|
|
|
|
3.1
|
|
Purchased Intangible Amortization
|
|
|
|
5.4
|
|
|
|
|
|
5.8
|
|
|
|
|
|
20.7
|
|
|
|
|
|
22.0
|
|
Other Costs
|
|
|
|
0.9
|
|
|
|
|
|
27.3
|
|
|
|
|
|
6.8
|
|
|
|
|
|
37.0
|
|
Total Non-GAAP Adjustments:
|
|
|
$
|
20.3
|
|
|
|
|
$
|
33.8
|
|
|
|
|
$
|
57.3
|
|
|
|
|
$
|
63.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Operating Income
|
|
|
$
|
81.3
|
|
|
|
|
$
|
73.0
|
|
|
|
|
$
|
205.5
|
|
|
|
|
$
|
219.0
|
|
Non-GAAP Operating Margin
|
|
|
|
14.7
|
%
|
|
|
|
|
14.1
|
%
|
|
|
|
|
11.2
|
%
|
|
|
|
|
12.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Interest & Other Income (Expense), net
|
|
|
|
(7.2
|
)
|
|
|
|
|
(4.7
|
)
|
|
|
|
|
(26.0
|
)
|
|
|
|
|
(19.9
|
)
|
Non-GAAP Profit Before Tax
|
|
|
|
74.1
|
|
|
|
|
|
68.3
|
|
|
|
|
|
179.5
|
|
|
|
|
|
199.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Income Tax Provision
|
|
|
|
(21.2
|
)
|
|
|
|
|
(21.1
|
)
|
|
|
|
|
(48.5
|
)
|
|
|
|
|
(60.1
|
)
|
Non-GAAP Tax Rate
|
|
|
|
28.6
|
%
|
|
|
|
|
30.9
|
%
|
|
|
|
|
27.0
|
%
|
|
|
|
|
30.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority Interest
|
|
|
|
(0.7
|
)
|
|
|
|
|
(0.5
|
)
|
|
|
|
|
(1.7
|
)
|
|
|
|
|
(0.7
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Net Income Attributable to Bruker
|
|
|
|
52.2
|
|
|
|
|
|
46.7
|
|
|
|
|
|
129.3
|
|
|
|
|
|
138.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares Outstanding (Diluted)
|
|
|
|
169.0
|
|
|
|
|
|
167.7
|
|
|
|
|
|
168.5
|
|
|
|
|
|
167.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Earnings Per Share
|
|
|
$
|
0.31
|
|
|
|
|
$
|
0.28
|
|
|
|
|
$
|
0.77
|
|
|
|
|
$
|
0.83
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP to Non-GAAP Gross Profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Gross Profit
|
|
|
$
|
235.9
|
|
|
|
|
$
|
241.7
|
|
|
|
|
$
|
805.2
|
|
|
|
|
$
|
829.4
|
|
Non-GAAP Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring Costs
|
|
|
|
7.1
|
|
|
|
|
|
(0.4
|
)
|
|
|
|
|
7.1
|
|
|
|
|
|
-
|
|
Acquisition-Related Costs
|
|
|
|
0.3
|
|
|
|
|
|
0.2
|
|
|
|
|
|
0.9
|
|
|
|
|
|
3.2
|
|
Purchased Intangible Amortization
|
|
|
|
5.0
|
|
|
|
|
|
4.9
|
|
|
|
|
|
19.3
|
|
|
|
|
|
18.6
|
|
Other Costs
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
0.1
|
|
Total Non-GAAP Adjustments:
|
|
|
|
12.4
|
|
|
|
|
|
4.7
|
|
|
|
|
|
27.3
|
|
|
|
|
|
21.9
|
|
Non-GAAP Gross Profit
|
|
|
$
|
248.3
|
|
|
|
|
$
|
246.4
|
|
|
|
|
$
|
832.5
|
|
|
|
|
$
|
851.3
|
|
Non-GAAP Gross Margin
|
|
|
|
45.0
|
%
|
|
|
|
|
47.6
|
%
|
|
|
|
|
45.3
|
%
|
|
|
|
|
47.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP to Non-GAAP Interest & Other Income
(Expense), net
|
|
|
|
|
|
|
|
|
GAAP Interest & Other Income (Expense), net
|
|
|
$
|
(7.2
|
)
|
|
|
|
$
|
(4.7
|
)
|
|
|
|
$
|
(23.6
|
)
|
|
|
|
$
|
(17.7
|
)
|
Non-GAAP Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Insurance Settlement
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
(1.5
|
)
|
|
|
|
|
-
|
|
Sale of Product Line
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
(0.9
|
)
|
|
|
|
|
(2.2
|
)
|
Total Non-GAAP Adjustments:
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
(2.4
|
)
|
|
|
|
|
(2.2
|
)
|
Non-GAAP Interest & Other Income (Expense), net
|
|
|
$
|
(7.2
|
)
|
|
|
|
$
|
(4.7
|
)
|
|
|
|
$
|
(26.0
|
)
|
|
|
|
$
|
(19.9
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Please refer to our press release for a full explanation for the
use of non-GAAP measures.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Source: Bruker Corporation